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Somatic Activating Mutations in GNAQ and GNA11
Are Associated with Congenital Hemangioma
Ugur M. Ayturk,1,2,9 Javier A. Couto,3,9 Steven Hann,1 John B. Mulliken,3,4 Kaitlin L. Williams,1
August Yue Huang,1,2 Steven J. Fishman,4,5 Theonia K. Boyd,6 Harry P.W. Kozakewich,4,6
Joyce Bischoff,5,7 Arin K. Greene,3,4 and Matthew L. Warman1,2,4,8,*
Congenital hemangioma is a rare vascular tumor that forms in utero. Postnatally, the tumor either involutes quickly (i.e., rapidly invo-
luting congenital hemangioma [RICH]) or partially regresses and stabilizes (i.e., non-involuting congenital hemangioma [NICH]). We
hypothesized that congenital hemangiomas arise due to somatic mutation and performed massively parallel mRNA sequencing on
affected tissue from eight participants. We identified mutually exclusive, mosaic missense mutations that alter glutamine at amino
acid 209 (Gln209) in GNAQ or GNA11 in all tested samples, at variant allele frequencies (VAF) ranging from 3% to 33%. We verified
the presence of the mutations in genomic DNA using a combination of molecular inversion probe sequencing (MIP-seq) and digital
droplet PCR (ddPCR). The Gln209 GNAQ and GNA11 missense variants we identified are common in uveal melanoma and have
been shown to constitutively activate MAPK and/or YAP signaling. When we screened additional archival formalin-fixed paraffin-
embedded (FFPE) congenital cutaneous and hepatic hemangiomas, 4/8 had GNAQ or GNA11 Gln209 variants. The same GNAQ or
GNA11 mutation is found in both NICH and RICH, so other factors must account for these tumors’ different postnatal behaviors.Congenital hemangiomas are rare vascular tumors that are
present at birth. They are different from common infantile
hemangiomas that rapidly enlarge postnatally and immu-
nostain for the cell surface marker GLUT1.1 In contrast,
congenital hemangiomas are GLUT1 negative and display
one of two clinical patterns: ‘‘rapidly involuting congenital
hemangioma’’ (RICH)2,3 or ‘‘non-involuting congenital
hemangioma’’ (NICH).4 RICH can be detected prenatally
(as early as 12 weeks gestation) and presents in a newborn
as a raised, gray-violaceous solitary cutaneous tumor with
fine telangiectasias, ectatic veins, and a pale halo (Figure 1).
RICH demonstrates fast-flow and can be associated with
congestive cardiac failure and transient low-grade throm-
bocytopenia. If there are not overwhelming complications
from heart failure or hemorrhagic ulceration, the tumor
rapidly regresses by 6–14months, leaving a patch of subcu-
taneous atrophy, dilated veins, and persistent fast-flow.
RICH is also well documented to occur in the liver
(Figure 1), where it spontaneously regresses just as in
skin.5 The second category of congenital hemangioma
(NICH) presents as a well-circumscribed, plaque-like tumor
with a purple-pink hue, pale rim, coarse telangiectasia, and
fast-flow (Figure 1). It remains unchanged throughout
childhood; however, there are uncommon examples of
growth and expansion in adolescence.6 In some cases
RICH can cease regressing and transform into NICH.7,8
There are histopathological similarities between RICH
and NICH (Figure 1) and between congenital hemangioma
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hepatic congenital hemangioma.9
We hypothesized that somaticmutations initiate the for-
mation of congenital hemangiomas and searched for these
mutations by performingmassively parallel sequencing on
fresh frozen specimens.
The Committee on Clinical Investigation of Boston
Children’s Hospital approved this study. Congenital hem-
angioma samples were collected during a clinically indi-
cated procedure, and all participants provided written con-
sent. Tissues were immediately flash-frozen or placed in
RNAlater (Thermo Fisher Scientific) and stored at 80C
until further processing. The original intent was to perform
RNA-seq looking for coding sequence mutations or genetic
alterations that might produce chimeric or miss-spliced
transcripts and to perform whole-exome sequencing
(WES) looking for coding sequence mutations in genes
that were not highly expressed in affected tissue. RNA-
seq libraries were prepared via standard Illumina TruSeq
protocols and sequenced on one flowcell of an Illumina
HiSeq 2500 system. We did not perform WES because we
were able to successfully identify mutations with RNA-seq.
We generated 32–47million 100-bp paired-end reads per
RNA-seq library. Following the Genome Analysis Toolkit
(GATK) best practices workflow,10 we mapped each set of
reads to the reference human genome (GRCh37) with
STAR aligner,11 removed PCR duplicates with Picard, real-
igned the reads around small insertions and deletions,
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Figure 1. Representative Gross and His-
tological Images of RICH, NICH, and Soli-
tary Congenital Hepatic Hemangioma
from Three Participants
Shown are RICH (A–C), NICH (D–F), and
solitary congenital hepatic hemangioma
(G–I).
(A) Supraorbital purple tumor with central
depression and ulceration in a 1-week-old
infant (participant 8 with RICH).
(B) Hematoxylin and eosin (H&E) staining
of the affected tissue imaged at 1003
reveals small lobules (arrows) surrounded
by abundant dense fibrous tissue where
lobules have involuted and only draining
channels remain (asterisks).
(C) H&E staining at 4003 reveals lobular
capillaries containing enlarged lumens
and minimally prominent endothelium.
(D) Raised erythematous nodule at the left
nasal ala in a 5-year-old child (participant
4 with NICH).
(E) H&E staining at 1003 reveals a large
lobule (arrows) with prominent intra-
and peri-lobular channels (asterisks).
(F) H&E staining at 6003 shows a hob-
nailed endothelium (arrows) lining lobular
channels surrounded by fibrous tissue.
(G) Excised 5 cm hepatic mass with pallor,
extensive infarction, focal calcification,
and hemorrhage in a 4-month-old infant
(participant 16 with hepatic RICH).
(H) H&E staining at 203 reveals a highly vascular rim superiorly and an acellular infarcted and hemorrhagic zone inferiorly.
(I) H&E staining at 4003 shows a minimally prominent endothelium lining widened hepatic sinusoids (asterisks) with cords containing
a few bile ducts (arrowheads) but devoid of hepatocytes.then compiled single-nucleotide variant lists with Sam-
tools13 and identified positions with a minimum of 203
read depth, 33 variant read depth, and 10% variant allele
frequency using VarScan.14 We removed variants with
greater than 40% variant allele frequency, assuming that
these changes most likely represent germline variants
rather than somatic changes. We further filtered the vari-
ants by removing those previously reported in the Exome
Variant Server (ESP6500), 1000 Genomes Project, ExomeTable 1. Variant Filtering Strategy Employed in the Analysis of RNA-S
Participant 1 2 3 4
Min 203 read depth,
33 var read depth,
10% var allele freq
56,331 49,047 40,440 38,348
Known variants filtered 24,333 18,454 12,671 12,893
Coding sequence
variants
279 208 234 253
Nonsynonymous
variants
172 120 144 138
Variants without strand
bias
133 83 94 105
Variants with <40%
allele freq
93 62 57 92
Genes with variants
in R3 samples, not
in negative controls
ATN1, B3GNT2, GNAQ, IL13RA1, NBPF11, PLEKHO1
790 The American Journal of Human Genetics 98, 789–795, April 7, 2Aggregation Consortium (v.0.3), and dbSNP as a non-clin-
ical entry (build 138). We annotated the remaining vari-
ants with ANNOVAR.15
A total of 43 genes exhibited protein sequence altering
variants in R3 of 8 specimens (Figure S1). We narrowed
this list further by comparing these variants to those found
in RNA-seq data from unrelated vascular lesions (arteriove-
nous malformation [n ¼ 3] and common infantile heman-
gioma [n¼1]). A total of 12 genes contained a variant foundeq Data
5 6 7 8 Average
37,672 32,473 39,380 26,900 40,074
11,756 10,206 11,236 9,570 13,890
241 276 261 348 263
134 155 164 221 156
99 114 110 167 113
70 92 87 139 87
, SMC4, SSC5D, TBX3, TCF7L2, TCHP, POLR2J2/UPK3BL 12
016
Table 2. Participants Screened for GNAQ and GNA11 Variants
Participant Phenotype Age Sex Location Source Variant RNA DNA (MIP-seq) DNA (ddPCR) Control DNA (ddPCR)
1 NICH 8 years male chest frozen tissue GNAQ p.Gln209Leu (c.626A>T) 2/6 (33%) – 101/1,853 (5%) 0/1,499 (0%)
2 NICH 9 years male neck frozen tissue GNAQ p.Gln209Pro (c.626A>C) 1/10 (10%) – 392/6,061 (6%) 0/2,215 (0%)
3 NICH 14 years female temple frozen tissue GNA11 p.Gln209Leu (c.626A>T) 15/124 (12%) 13/211 (6%) 84/1,042 (8%) 0/2,498 (0%)
4 NICH 5 years male nose frozen tissue GNAQ p.Gln209Leu (c.626A>T) 3/15 (20%) – 235/3,233 (7%) 0/2,359 (0%)
5 NICH 7 years male nose frozen tissue GNAQ p.Gln209Leu (c.626A>T) 7/51 (14%) – 61/759 (8%) –
6 NICH 2.5 years male neck frozen tissue GNA11 p.Gln209Leu (c.626A>T) 3/103 (3%) – 15/633 (2%) –
7 RICH 3 years male lower extremity frozen tissue GNAQ p.Gln209His (c.627A>C) 7/30 (23%) – – –
8 RICH 1 week male orbital area frozen tissue GNAQ p.Gln209Leu (c.626A>T) 6/31 (19%) – – –
9 NICH 12 years male lower extremity FFPE tissue GNAQ p.Gln209Pro (c.626A>C) – 1139/19,657 (6%) 125/1,089 (11%) –
10 NICH 14 months male lower extremity FFPE tissue NA – 3/1,383 (< 1%) 0/640 (0%) –
11 RICH 3 months male lower extremity FFPE tissue GNAQ p.Gln209Leu (c.626A>T) – - 26/717 (4%) –
12 NICH 3 years male ear FFPE tissue NA – 1/400 (< 1%) - –
13 RICH 2 weeks female upper extremity FFPE tissue NA – 2/772 (< 1%) 0/516 (0%) –
14 NICH 2 years male lower extremity FFPE tissue NA – 2/179 (1%) 0/152 (0%) –
15 RICH 2 weeks male lower extremity FFPE tissue GNA11 p.Gln209Leu (c.626A>T) – – 27/2,576 (1%) –
16 RICH 4 months male liver FFPE tissue GNA11 p.Gln209Leu (c.626A>T) – – 52/537 (10%) –
17 CHOR neonatal female placenta FFPE tissue NA – 0/850 (0%) – –
18 CHOR neonatal female placenta FFPE tissue NA – 3/1,855 (< 1%) – –
19 CHOR neonatal female placenta FFPE tissue NA – 3/1,875 (< 1%) – –
20 CHOR neonatal female placenta FFPE tissue NA – 7/2,233 (< 1%) – –
RNA and DNA (MIP-seq) columns indicate read depth, and DNA (ddPCR) column indicates number of droplets. The rate of variant/total alleles is also depicted in the aforementioned columns. For samples that were not
associated with a mutation (indicated with NA), available MIP-seq and ddPCR results with the lowest power (in terms of read depth and number of droplets) are depicted. Control DNA samples were retrieved from blood
or saliva. Abbreviations are as follows: NICH, non-involuting congenital hemangioma; RICH, rapidly involuting congential hemangioma; CHOR, chorangioma. Dash (–) indicates that the assay was not performed.
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Figure 2. Detection of theGNA11 c.626A>T (p.Gln209Leu) Allele in Congenital Hemangioma Specimen fromParticipant 3withNICH
(A) IGV screenshot indicating 12% variant allele frequency in GNA11 transcripts measured by RNA-seq. 1243 indicates the depth of
coverage at position 626.
(B) IGV screenshot indicating 6% variant allele frequency in GNA11 measured by MIP-seq. 2113 indicates the depth of coverage at
position 626.
(C) Water-negative control for the ddPCR assay shows no flourescence for GNA11 wild-type or variant alleles.
(D) ddPCR results of human DNA from unaffected control tissue indicates the presence of only the GNA11 wild-type allele.
(E) ddPCR results of congenital hemangioma indicates the presence of wild-type and variant (8%) alleles.only in the congenital hemangioma samples (Table 1).
The variants found in the other RNA-seq datasets were
assumed to be associated with RNA editing or with errors
in sequencing, mapping, or annotation. Close inspection
of variants in the 12 remaining genes for potential
mismapping, sequencing errors, and lack of evolutionary
conservation left only variants in GNAQ (MIM: 600998)
as likely true-positive somatic mutations (Tables 2 and
S1). GNAQ encodes guanine nucleotide binding pro-
teinG(q) alpha, a subunitwithin a complex thathydrolyzes
the intracellular messenger GTP to GDP. GNAQ shares
90% protein sequence similarity with GNA11 (MIM:
139313). Somatic missense mutations that alter codon
209 in GNAQ (GenBank: NP_002063.2) and GNA11
(GenBank: NP_002058.2) have been reported in >80% of
uveal melanomas.16,17 A different somatic mutation in
GNAQ (GRCh37; GenBank: NM_002072.4, NP_002063.2;
c.548G>A [p.Arg183Gln]) occurs in isolated capillary mal-
formations and in individualswith Sturge-Weber syndrome
(MIM: 185300).18 Stringent filtering revealed evidence for792 The American Journal of Human Genetics 98, 789–795, April 7, 2a GNAQ missense mutation in three of eight samples
(Figure S1). When we reanalyzed with less stringent
filtering, we found that six of eight samples had a somatic
GNAQ mutation and the remaining two samples had a
somatic GNA11mutation (Table 2).
We confirmed that the mutations were real by testing
DNA from six of eight samples via an orthologous method,
digital droplet PCR (ddPCR), and/or molecular inversion
probe sequencing (MIP-seq) (Table 2 and Figure 2). We per-
formed ddPCR (Table S2) as previously described19 and
consideredvariants present at frequenciesR1%to represent
true positives.We also verified that themutationswe identi-
fied are somatic by testing control DNA (extracted from
blood or saliva) of four participants via ddPCR (Table 2).
For MIP-seq, we enriched the genomic DNA samples for
the protein-coding sequences of GNAQ and GNA11 by hy-
bridization to probes (Table S3) containing an 8-nucleotide
barcode that uniquely identifies individual MIPs. MIP
capture and sequencing were performed as previously
described.20 Raw reads were mapped to the reference016
Figure 3. Mutant Allele Frequency in
Capillary-Enriched Lobules Is Higher than
That in the Surrounding Stromal Tissue
within Congenital Hemangioma
(A) Pre-laser capture image of NICH
showing multiple dermal vascular lobules
from participant 4 (staining dark blue in
hematoxylin and eosin-stained section,
320 magnification).
(B) Post-laser capture image of the section
depicted in (A) showing absence of virtu-
ally all vascular lobules (hematoxylin and
eosin-stained section, 320 magnification).
(C) Pre-laser capture of skeletal muscle,
fibrous tissue, and fat uninvolved tissue
by the NICH shown in (A) and (B) (hema-
toxylin and eosin-stained section, 320
magnification) that was resected en bloc.
(D) Graph depicting the GNAQ c.626A>T
allele frequencies in DNA extracted from
the capillary enriched lobules (A), the re-
sidual tissue (B), and the adjacent muscle
tissue (C) measured in triplicate by ddPCR
(dots). Solid lines indicate the average of
the three measurements.human genome sequence (GRCh37) with BWA; PCR
duplicates were removed with FastqMcf and Picard.
The minimum read depths for GNAQ c.626A>T and
GNA11 c.626A>T (GRCh37, GenBank: NM_002067.4)
were 2,0323 and 1793, respectively. We considered true
positive somatic variants to have allele frequencies >2%.
Using a combination of the aforementioned ddPCR and
MIP-seq assays, we also analyzed eight archival formalin-
fixed paraffin-embedded (FFPE) congenital hemangiomas
and four chorangioma samples. Four of the hemangiomas
contained a likely somatic GNAQ or GNA11 mutation,
whereas no such mutations were found in the choran-
giomas (Table 2).
Our findings expand the spectrum of genes and alleles
that are somatically altered in congenital vascular anoma-
lies (Figure S2).18–29 Of interest is that the same mutation
(i.e., GNAQ c.626A>T and GNA11 c.626A>T) occurs in
RICH and NICH, implying that other genetic, epigenetic,
and/or environmental factors probably influence these
lesions’ postnatal behavior. Because GNAQ and GNA11
mutations are common in highly metastatic uveal mela-
nomas,16,17 identifying factors that determine the post-
natal behavior of RICH and NICH might suggest new
strategies for treating uveal melanoma. Thus far, we
observed mutations affecting Gln209 in GNAQ or GNA11
only in congenital hemangioma, whereas we and other
investigators18,30,31 have identified mutations affecting
Arg183 only in capillary malformations. Our data indicate
that, with respect to congenital hemangiomas, GNAQ and
GNA11 have functional overlap. Consistent with func-
tional overlap in nonmalignant conditions, somatic muta-
tions affecting either codon 183 or 209 in GNAQ and
GNA11 have also been found in phakomatosis pigmento-The Amvascularis and extensive dermalmelanocytosis.32 However,
a role for GNA11 that does not overlap with that of GNAQ
can be inferred from recent studies of inherited hypocalce-
mia and hypercalcemia caused bymutations in GNA11 but
not GNAQ.33–36 In vitro studies indicated that missense
mutations altering Arg183 and Gln209 both activate GTP-
dependent signaling, but might do so via different path-
ways and with different efficiency.18,37,38 Therefore, it is
critical to understand the cell-type-specific, context-spe-
cific, and allele-specific effects of somatic GNAQ or GNA11
mutations during vasculogenesis. For example, the GNAQ
c.548G>A (p.Arg183Gln) mutation in sporadic capillary
malformations was shown to be enriched in endothelial
cells that line blood vessels,30 whereas in lymphatic mal-
formations activating PIK3CA (MIM: 171834), mutations
were present in the lymphatic endothelial cells.39,40,41 To
determine which features within a congenital hemangi-
oma sample are enriched for mutant cells, we performed
laser capture microdissection on a FFPE tissue section
from participant 4. We observed a mutant allele frequency
of 13% in the vascular-enriched lobules within the lesion,
whereas the remaining tissues exhibit less than 2%mutant
allele frequency (Figure 3).
We were unable to identify strongly suggestive GNAQ or
GNA11 mutations in 4/16 congenital hemangiomas, lead-
ing us to conclude that the frequency of mutated cells in
some specimens was either below our threshold of detec-
tion or that congenital hemangiomas exhibit further locus
heterogeneity. Although our sample size for chorangiomas
is small, our data indicate that chorangioma is probably
not the placental counterpart of congenital hemangiomas
associated with mutations altering Gln209 in GNAQ or
GNA11.erican Journal of Human Genetics 98, 789–795, April 7, 2016 793
In contrast to an earlier study in which we detected
somatic mutations in PIK3CAwith WES but not with RNA-
seq,23 RNA-seq was useful in this study. For WES, the sensi-
tivity of detecting somaticmutations is dependent ondepth
of coverage and frequency of mutant cells (Figure S3). Inter-
estingly, when we compared the relative frequencies of the
GNAQ andGNA11mutant allele at the RNA andDNA levels
in the affected tissue specimens for which we had paired
RNA and DNA, the mutant allele frequency was always
higher in the RNA (Table 2). This latter finding is compatible
withmutation-containingcellswithin theaffected tissue ex-
pressing GNAQ or GNA11 at a greater level relative to other
cells. Thus, in addition to the advantages of using RNA-
seq to find mutations that produce abnormal splicing or
chimeric transcripts, RNA-seq can be advantageous for
detecting somatic coding sequence mutations.Supplemental Data
Supplemental Data include three figures and three tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
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